Journal Scans
Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases
Bevacizumab Appears Safe for NSCLC With Brain Metastases
MA Socinski , CJ Langer, JE Huang, MM Kolb, P Compton, L Wang, W Akerley
20090808
2009 Sept 8
J Clin Oncol
Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases
J Clin Oncol. 2009 Sept 8; Epub ahead of print, MA Socinski , CJ Langer, JE Huang, MM Kolb, P Compton, L Wang, W Akerley
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Bevacizumab is approved for use as first-line treatment for patients with unresectable, locally advanced, recurrent or metastatic non–small-cell lung cancer (NSCLC) when combined with carboplatin and paclitaxel. Among patients with advanced NSCLC, 30% to 40% will develop brain metastasis, which confers a poor prognosis. Patients with NSCLC and brain metastasis have been excluded from clinical trials of bevacizumab because of concerns of increased risk of intracranial hemorrhage. Although selected...
